Core Insights - Werewolf Therapeutics is advancing its clinical-stage programs, particularly WTX-124 and WTX-330, with significant milestones expected in the second half of 2025 [2][6][4] - The company is also developing proprietary INDUCER T cell engager molecules, with a candidate expected to be nominated by the end of Q2 2025 [2][7] - Financial guidance indicates sufficient cash runway into Q4 2026, with cash and cash equivalents reported at $92.0 million as of March 31, 2025 [11][17] Clinical Development - WTX-124 is a conditionally activated Interleukin-2 (IL-2) molecule being evaluated as a monotherapy and in combination with pembrolizumab for various solid tumors [3][9] - WTX-330, an Interleukin-12 (IL-12) molecule, has initiated patient dosing in a Phase 1b/2 trial to optimize its exposure in the tumor microenvironment [4][6] - The company plans to present interim data from the WTX-124 trial in the second half of 2025, focusing on tolerability and response rates [6] Financial Performance - For Q1 2025, research and development expenses were $13.1 million, slightly up from $12.9 million in Q1 2024 [11][15] - General and administrative expenses decreased to $4.9 million in Q1 2025 from $5.0 million in Q1 2024 [11][15] - The net loss for Q1 2025 was $18.1 million, compared to a net loss of $16.2 million in the same period of 2024 [11][15] Strategic Initiatives - The company is launching an educational campaign in May to raise awareness about skin cancer and the differentiation of its therapeutics [2][6] - Werewolf's proprietary PREDATOR masking technology is designed to enhance the safety and efficacy of its T cell engagers by silencing peripheral activity [2][7]
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update